⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TAK News
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight
globenewswire.com
AZN
NVS
ABBV
BMY
GILD
REGN
VRTX
BIIB
JNJ
MRK
ARWR
TAK
VERA
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO ® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
businesswire.com
TAK
eCOA: Has It Lived Up to the Promise? A Realistic Assessment for Today's Trials, Upcoming Webinar Hosted by Xtalks
prnewswire.com
MDT
TAK
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
prnewswire.com
TAK
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
prnewswire.com
TAK
2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable
prnewswire.com
TAK
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight
globenewswire.com
SNGX
IPHA
BMY
NKTX
AZN
MRK
TAK
NVS
GMAB
ABBV
BIIB
CRSP
INCY
ALKS
PFE
REGN
GILD
AMGN
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
businesswire.com
TAK
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
businesswire.com
TAK
Community Servings' AMPL Institute Releases National Food is Medicine Report on Access to Medically Tailored Nutrition in the U.S.
prnewswire.com
TAK